Recent Scientific Awards
TTUHSC President’s Young Investigator Research Award (2009)
TTUHSC School of Pharmacy, Distinguished Alumni Award; Excellence in Research (2010)
Invited Talk; Gordon Research Conference: Barriers of the CNS (2010): Drug delivery to metastatic brain tumors. Colby-Sawyer College, New Hampshire.
Invited Talk; Does Chemotherapy Reach Effective Concentrations for the Treatment of Brain Metastases of Breast Cancer? Medical Rounds – London Health Sciences Center. Invited Seminar and Discussion. London Ontario, Canada
Invited Talk; Breast Cancer Center of Excellence, Invited Panelist and speaker National Breast Cancer Coalition Fund, Annual Advocacy Training Conference, Washington DC.(2009)
Invited Talk; Challenges and Opportunities to Deliver Drugs in Brain Metastases of Breast Cancer, Invited Seminar, MD Anderson Houston TX (2009)
Invited Talk; Workshop on Drug Delivery in Parkinson’s Disease; Circumventing the Blood-brain barrier (2008):Michael J. Fox Foundation and the Kinetics foundation. San Francisco, CA.
Recent Educational Awards
American Association of Colleges of Pharmacy; Innovations in Teaching Award (2007)
Texas Higher Education Coordinating Board Star Award Finalist (2009)
TTUHSC President’s Excellence in Teaching Award (2008)
P3 Teacher of the Year; Texas Tech University HSC, SOP (2005, 2006, 2007, 2008)
P3 Teaching Team of the Year; Texas Tech University HSC, SOP (2005, 2006, 2007)
P1 Teaching Team of the Year; Texas Tech University HSC, SOP (2004)
About Paul Lockman
Clinical Toxicology, Anatomy and Pharmacology
Computational Chemistry and Molecular Modeling
The Computational Chemistry and Molecular Modeling Laboratory houses hardware and software necessary for the study of the properties of a wide range of chemical or biological interest. The Laboratory provides researchers in the chemical, biological, and pharmaceutical sciences located in West Virginia access to both local and remote access to computational facilities.
Ongoing research in this area applies biological and physical science principles to the design and optimization of drug delivery. The overall goal is to maximize therapeutic drug utilization over a defined time period with minimal side effects. The following factors are considered when formulating and evaluating drug delivery systems:
Suitable dosage form design
Appropriate route of administration
Utilization of certain biochemical and physiological processes to aid drug delivery
Possible chemical derivatives of the drug
Careful control of these variables allows pharmaceutical scientists to modify the rate, extent, and site of the therapeutic effects of drugs. Advances in polymer sciences and molecular biology are leading to the design and formulation of better and more sophisticated delivery systems. Modern research laboratories and instrumentation, including cell culture facilities, cell and molecular biology-related equipment, dissolution and solid-state analysis, and dosage form manufacturing facilities, are available.
Drug Metabolism and Pharmacokinetics
A significant research focus of the Department is on the study of human drug metabolizing enzymes, including the cytochrome P450 family. One aspect of these studies is to investigate the structural basis for the function of P450 enzymes using a combination of molecular modeling and experimental methods, such as heterologous expression, site-directed mutagenesis and biochemical assays. Further in vitro studies include enzyme kinetics and the application of NMR, mass spectrometry and stable isotopes to drug metabolism studies and P450 structure elucidation. This research has a potential for advancing our understanding of how P450 enzymes activate or deactivate drugs and xenobiotics, with important implications for drug-drug interactions and metabolic activation of carcinogens.
For the CV's of Drug Metabolism and Pharmacokinetics Faculty, please view:
Studies are being conducted to understand how modification of DNA causes disease. This work entails identifying DNA modifications, determining how they form, and their relationship to a disease state. Research is also in progress to develop antisense and triplex DNA-based agents to treat gene-based diseases such as HIV. To conduct these research activities, a variety of tools are employed including organic synthesis, nuclear magnetic resonance spectroscopy, electron spin resonance spectroscopy, mass spectrometry, computational chemistry, and molecular biology techniques. The application of these techniques has led to the design of novel and unique solutions to current research problems.
Grants and Research
Chemotherapy distribution into brain tumors and metastases
Nanoparticle drug delivery to brain
Effects of nicotine and or smoking on drug distribution
Recent and Current Funding
biOasis; Drug Company Contract “Brain Uptake and In Vivo Activity of a p97-anti HER2 mAbs Conjugate (BTA-p97) in Brain Metastases of Breast Cancer; Survival Project”
National Cancer Institute, National Institutes of Health, Bethesda, MD. 1R01CA166067-01A1 “Prevention and Treatment of Brain Micro-metastases of Breast Cancer”
NEKTAR Therapeutics; Drug company contract “Pharmacokinetics and efficacy of NEKTAR-102 in brain metastases of breast cancer”
biOasis; drug company contract “Brain Uptake and In Vivo Activity of a p97-anti HER2 mAbs Conjugate (BTA-p97) in Brain Metastases of Breast Cancer”
Department of Defense, Breast Cancer Research Program. #BC096887. Cationic Chemotherapeutics to Penetrate Both the Blood-Brain Barrier and Brain Metastasis of Breast Cancer Cells via the Choline Transporter.
Department of Defense, Breast Cancer Research Program. # BC050006. Blood-Tumor Barrier Characterization and Nanoparticle Drug Delivery in Brain Metastasis of Breast Cancer.
Microtransponder; Medical Device Grant “Feasibility of microstimulation for targeted BBB disruption.”
Minority Health Research and Education Grant program. State of Texas Board of Higher Education; Minority Health Research and Education Grant. Innovations in Competency Education: Strengthening the Pipeline.
National Institute on Drug Abuse, National Institutes of Health, Bethesda, MD. U19 MH069059-01. Development of Novel Treatments for Nicotine Addiction.”